2 amplify the 5'-end of SEMA6C cDNA from a pool of adult human brain cDNAs. Fortunately, a 1.5kb product was obtained. This led to obtain the entire coding sequence of SEMA6C. To obtain its full length cDNA, we performed 5'-RACE procedure to sequence the additional 5'-UTR of SEMA6C cDNA from the oligo(dT) primed human brain mRNA with a gene specific primer (antisense to SEMA6C.1 nucleotides 353-377) and a nested primer (antisense to SEMA6C.1 nucleotides . A new generation of SMART™ RACE cDNA Amplification Kit(Clontech) was used. MMLV reverse transcriptase Superscript II (Gibco) was used to perform the reverse transcription of human brain mRNA(Clontech) following the protocol. 1µl of total human brain mRNA was used to start the reverse transcription. After the resulting fragments were cloned into pGEM-T vector for sequencing, two sets of primers were used to confirm existence of the predicted cDNA sequence of SEMA6C and to amplify its coding sequence (CDS) from human brain cDNA. This led to extension of 143bp at 5' end of the above sequence. Then two sets of primers were used to confirm existence of the predicted cDNA sequence of SEMA6C and to amplify its cds from human brain cDNA libraries. To our surprise, three splicing variants of SEMA6C were obtained, here named SEMA6C.1, SEMA6C.2 and SEMA6C.3, respectively (Fig.1 ).
The 3845bp sequence (SEMA6C.1, the longest isoform) contained an open reading frame capable of encoding a 962 amino acid polypeptide with a predicted molecular weight of 104.3kDa. The 3'-non-coding region was 795 bp in size. The 3'-terminal of the sequence contained a typical poly(A) addition signal, AATAAA, which precedes multiple A nucleotides at the end of the sequence. The initiating ATG codon (nucleotides 162-164) is preceded by more than one in-frame TGA stop codons and surrounded by a sequence (AGGATGC) that represents a good match with the consensus proposed by Kozak (1) for initiation translation.
In course of the study, a cDNA sequence (3407bp) with accession number of AB022434 was released in GenBank on 11- JAN-2001 . Alignment analysis shows that it represents the same isoform to SEMA6C.2 we isolated.
In order to look into whether any SEMA6C-related semaphorins remained to be identified, human semaphorin SEMA6C sequence was used to search against the nonredundant GenBank database (Blastn and Blastp), and three overlapping human cDNA fragments (AB040912, AK022831 and AK022747) were identified. This led to a contig of 4082bp(including 11A), capable of encoding a 464 aa polypeptide which is moderately homologous to C-terminal of the 962aa polypeptide above. It seemed that this was a part of an unidentified semaphorin gene. To clone a cDNA coding for the entire open reading frame of the gene, we performed a database search through dbEST and non-redundant GenBank database again. Only a partial cDNA (AK021660) of 1588bp was retrieved, in which a fragment of 25bp was identical to the first 25bp of the above 4082-bp sequence. Since the 1588bp cDNA fragment can encode a partial polypeptide of 367 aa, which show high homologous to the classic sema domain, and genomic sequence analysis showed that the distance between the 1588bp-fragment and the 4082bp-fragment was only 390bp, both of them may represent the same gene. However, it seemed that the 1588bp-fragment contained a stop codon and a part of its own 3' UTR, supporting that it came from a different gene. To evaluate the two possibilities, we designed two sets of primers based on the 1588bp-and 4082bp-fragments to perform RT-PCR using a pool of brain cDNAs as template. The two putative sequences probably derived from alternative splicing were confirmed using two sets of primers: P3: 5'-CGAAGACAAAGTGCCAAAGCCAAGG-3' (sense), P4: 5'-ACCAGCCACAATACGGGTCACGAGA-3' (antisense); P5: 5'-TAAAACCTCCATCGATTTCCCGG-3'(sense), P6: 5'-ACTCATCAACCATTCACCCCCCT-3' (antisense), which should give PCR products of 4 533bp and 493bp, respectively. Surprisingly, both of the predicted fragments (533bp and 493bp) were obtained, indicating the existence of the two sequences. They may be the two isoforms of a novel human semaphorin cDNA derived from alternative splicing. Thus, the putative long isoform could be extended to 5223kb, but still lacked an initiation codon.
Therefore, 5'-RACE technique was used to extend towards the 5' end of the sequence and obtain its full-length cDNA with a set of primers (antisense to SEMA6D.1 nucleotides 912-934 and 767-793, respectively). After cloning of the 5'-RACE products, three clones carried inserts overlapping the above 5223bp-sequence, suggesting the existence of the complete CDSs of 3036bp and 1431bp. Then three sets of primers and the oligo(dT) primed human brain mRNA were used to confirm the existence of the full-length cDNAs for the two isoforms and their CDSs. As predicted, the short isoform cDNA we obtained was 2290bp, which we designated SEMA6Ds (Fig.1 ).
To our surprise again, similar to SEMA6C, RT-PCR with the primers for the long isoform led to four distinct sequences, encoding 1011aa, 998aa, 1017aa and 1073aa, respectively. As shown in Fig. 1 , the presumed initiating ATG in SEMA6D.1 was assigned to nucleotides 440-442 because of the occurrence of ACC upstream and the presence of an inframe TGA stop codon, which is characteristic of favorable translation initiation sites (Fig.2) .
The 3'-terminal of the sequence contained a typical poly(A) addition signal, AATAAA, which precedes multiple A nucleotides at the end of the sequence. It is also noteworthy that the long 3' UTR (2452bp) contained six potential mRNA instability motifs (ATTTA), which presumably influence RNA half-life. The AUUUA motif is a highly conserved sequence repeated more than once in the 3' UTR of RNAs encoding many short-lived cytokines and protooncogenes (2). The unusually long 3' UTR of near 2.5kb accounting for 41.3% of SEMA6D.1 cDNA could also be significant, since the length of the 3' UTR is known to determine translational efficiency and mRNA instability (3). It is well known that expression 5 of cytokines and oncogenes is finely controlled, and they are usually rapidly expressed and degraded. In addition to transcriptional and translational regulation, modulation of mRNA turnover is an important reostat of gene expression by altering the amount of translatable mRNA.
Note: All of the amplified PCR products were cloned into pGEM-T plasmid (Promega) for sequencing. Plasmid DNA was isolated for sequencing using a plasmid preparation kit (Qiagen). DNA sequencing was performed by dideoxynucleotide sequencing system using the ABI PRISM™ Dye Terminator, dRhodamine terminator, or Big Dye Terminator cycle sequencing ready reaction kits (Perkin-Elmer). Sequencing was carried out on an ABI Prism 377-XL DNA sequencer (Perkin-Elmer).
Sequence analysis of human SEMA6C and SEMA6D
The sequence alignment and phylogenetic tree among mammalian class semaphorin proteins were performed using the program CLUSTAL W. Protein subsequence motifs were identified using the network service SMART (URL: http://smart.embl-heidelberg.de/). Prosite information of the proteins was analyzed with the URL " TMpred program" (Prediction of Transmembrae Regions and Orientation) which was used to make a prediction of membranespanning egions and their orientation. Amino acid sequence alignment of (HSA)SEMA6D.1, (HSA)SEMA6C.1, rat Sema6C and mouse Sema6C shows that the most conserved region is located in their extracellular domains, i.e. sema domain and PSI domain (Fig.3 ).
RNA master blot analysis
To determine the expression patterns of SEMA6C and SEMA6D in more normal human tissues and cancer cell lines, a master dot blot containing a total of 68 normal tissues and eight human cancer lines was hybridized respectively to the probes below: The DNA templates for After washed, the blots were exposed to X-ray film at -70ºC with an intensifying screen. For a given tissue, the relative amount of the transcription of SEMA6C or SEMA6D was estimated by the percent of its OD value vs. total OD value. In details, the exposed X-ray film was scanned into computer, and the OD value for positive signals was detected using PD-Quest (Bio-Rad) software for Dot blot analysis.
As shown in Fig.4 -A, SEMA6C was only strongly expressed in skeletal muscle, but much lowly in other adult and fetal tissues and in the eight human cancer lines examined so far. When the common probe above for SEMA6D was used, the results of dot blot analysis are shown in Fig4-B. Quantitative analysis revealed that it was highly expressed in kidney, placenta, skeletal muscle and almost all areas of the adult brain, and moderately in ovary, pancreas, thyroid gland, pituitary gland and almost all areas of the adult heart. It was also lowly expressed in alimentary canal, spinal cord, etc, but hardly detectable in aorta, spleen, thymus, bone marrow, peripheral blood leukocytes and eight human cancer lines. In addition, when the SEMA6Ds specific-probe was used, it was observed that similar to long isoforms of SEMA6D, SEMA6Ds was expressed relatively highly in adult kidney, relatively highly in 7 adult pancreas, heart (interventricular septum) and liver, moderately in placenta and mammary gland, and hardly detectable in fetal tissues, eight human cancer cell lines and most of other adult tissues.
When the expression levels between the seven adult tissues and the corresponding fetal tissues were compared, it was observed that only in lung the expression level of SEMA6D is significantly development-dependent. The expression level of SEMA6D in fetal lung was about 3-fold higher than that in adult lung. GCTGGCAGGGGCATGGTGAGGAGGAAGGTAGCTCAGTGGCATTTCTGAGCAGGGGCCACCCTGACTTCACCTTGGCCCACCATGAGGGTC 448
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